Total Payments
$18,183
2024 Payments
$9,926
Companies
42
Transactions
220
Medicare Patients
2,067
Medicare Billing
$374,317
Payment Breakdown by Category
Research$9,960 (54.8%)
Food & Beverage$4,853 (26.7%)
Travel$3,338 (18.4%)
Education$32.27 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,960 | 15 | 54.8% |
| Food and Beverage | $4,853 | 190 | 26.7% |
| Travel and Lodging | $3,338 | 14 | 18.4% |
| Education | $32.27 | 1 | 0.2% |
Payments by Type
Research
$9,960
15 transactions
General
$8,223
205 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $7,648 | 3 | $0 (2024) |
| Novo Nordisk AS | $4,503 | 20 | $0 (2022) |
| Merck Sharp & Dohme LLC | $2,417 | 17 | $0 (2024) |
| Lilly USA, LLC | $785.45 | 40 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $429.15 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $222.96 | 9 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $198.22 | 12 | $0 (2019) |
| GlaxoSmithKline, LLC. | $188.04 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $159.28 | 7 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $144.84 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,926 | 41 | Eli Lilly and Company ($6,918) |
| 2023 | $1,585 | 46 | Eli Lilly and Company ($730.01) |
| 2022 | $2,831 | 40 | Novo Nordisk AS ($2,312) |
| 2021 | $463.99 | 22 | Eisai Inc. ($91.72) |
| 2020 | $317.46 | 15 | Lilly USA, LLC ($84.73) |
| 2019 | $368.35 | 19 | Sunovion Pharmaceuticals Inc. ($62.55) |
| 2018 | $328.40 | 17 | Sunovion Pharmaceuticals Inc. ($85.58) |
| 2017 | $2,364 | 20 | Novo Nordisk AS ($2,191) |
All Payment Transactions
220 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $34.21 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: RESPIRATORY | ||||||
| 12/02/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.33 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $234.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $56.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $738.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | Cash or cash equivalent | $455.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $234.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $148.02 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $120.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $62.76 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2024 | Eli Lilly and Company | — | — | In-kind items and services | $23.95 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 10/03/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,894.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $56.74 | General |
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $21.62 | General |
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $7,648 | 3 |
| EX9924-4473 | Novo Nordisk AS | $1,519 | 7 |
| NN9535-4352 | Novo Nordisk AS | $792.50 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 604 | 1,490 | $241,573 | $115,375 |
| 2022 | 9 | 547 | 1,355 | $226,722 | $101,783 |
| 2021 | 8 | 453 | 997 | $163,113 | $76,251 |
| 2020 | 9 | 463 | 1,082 | $171,789 | $80,909 |
Total Patients
2,067
Total Services
4,924
Medicare Billing
$374,317
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 143 | 616 | $58,520 | $35,637 | 60.9% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 130 | 152 | $34,200 | $22,601 | 66.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 325 | $65,000 | $21,337 | 32.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 89 | 100 | $35,000 | $12,721 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 158 | $17,380 | $10,022 | 57.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 79 | 87 | $23,673 | $8,398 | 35.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 23 | 23 | $3,450 | $3,228 | 93.6% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 12 | 29 | $4,350 | $1,430 | 32.9% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 103 | 511 | $48,545 | $26,644 | 54.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 90 | 112 | $39,200 | $18,090 | 46.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 75 | 284 | $56,800 | $17,042 | 30.0% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 82 | 100 | $22,500 | $13,423 | 59.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 67 | 149 | $16,390 | $9,998 | 61.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 86 | 109 | $29,657 | $9,758 | 32.9% |
| 99335 | Established patient custodial care facility, group care, or assisted living visit, typically 25 minutes | Office | 2022 | 17 | 63 | $9,450 | $3,654 | 38.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 14 | 14 | $2,100 | $2,011 | 95.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $2,080 | $1,162 | 55.8% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 87 | 383 | $36,385 | $20,180 | 55.5% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 82 | 91 | $20,475 | $12,075 | 59.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 70 | 78 | $27,071 | $11,570 | 42.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 52 | 173 | $34,600 | $10,634 | 30.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 122 | $13,420 | $8,353 | 62.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 64 | 71 | $19,312 | $6,516 | 33.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 26 | 26 | $3,900 | $3,812 | 97.7% |
| 99335 | Established patient assisted living visit, typically 25 minutes | Office | 2021 | 20 | 53 | $7,950 | $3,109 | 39.1% |
About Dr. Etsegenet Ayele, M.D
Dr. Etsegenet Ayele, M.D is a Internal Medicine healthcare provider based in Los Alamitos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588752778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Etsegenet Ayele, M.D has received a total of $18,183 in payments from pharmaceutical and medical device companies, with $9,926 received in 2024. These payments were reported across 220 transactions from 42 companies. The most common payment nature is "" ($9,960).
As a Medicare-enrolled provider, Ayele has provided services to 2,067 Medicare beneficiaries, totaling 4,924 services with total Medicare billing of $374,317. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Los Alamitos, CA
- Active Since 10/11/2006
- Last Updated 01/15/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588752778
Products in Payments
- LAGEVRIO (Biological) $2,374
- Tresiba (Drug) $2,191
- Rybelsus (Drug) $1,519
- Ozempic (Drug) $879.19
- HETLIOZ (Drug) $392.99
- JARDIANCE (Drug) $334.14
- MOUNJARO (Drug) $235.16
- ENTRESTO (Drug) $133.10
- APTIOM (Drug) $132.61
- QUVIVIQ (Drug) $120.89
- TRADJENTA (Drug) $116.99
- SHINGRIX (Biological) $114.54
- Vascepa (Drug) $112.00
- TRULICITY (Drug) $99.54
- NUEDEXTA (Drug) $98.93
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $72.65
- EMGALITY (Drug) $67.38
- GVOKE PFS (Drug) $67.34
- BAQSIMI (Drug) $66.49
- Dayvigo (Drug) $65.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Los Alamitos
Dr. Rebekah Neal-Kraal, M.d, M.D
Internal Medicine — Payments: $42,492
Internal Medicine $42,492
Dr. Steven Becker, D.o, D.O
Internal Medicine — Payments: $11,752
Internal Medicine $11,752
Robert Lee, M.d, M.D
Internal Medicine — Payments: $9,928
Internal Medicine $9,928
Harold Lin, M.d, M.D
Internal Medicine — Payments: $8,765
Internal Medicine $8,765
Karyn Haitz
Internal Medicine — Payments: $7,817
Internal Medicine $7,817
Jack Rubin, M.d, M.D
Internal Medicine — Payments: $7,388
Internal Medicine $7,388